T0318

Tranilast

≥98% (HPLC), powder

• Synonym(s): 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid, 3,4-DAA, N-(3,4-Dimethoxycinnamoyl)anthranilic acid, Rizaben, SB-252218
• Empirical Formula (Hill Notation): C₁₈H₁₇NO₅
• CAS Number: 53902-12-8
• Molecular Weight: 327.33
• MDL number: MFCD00864787
• UNSPSC Code: 41106500
• PubChem Substance ID: 24278719
• NACRES: NA.77

Properties

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• mp: 166.2-168.2 °C (lit.)
• solubility: DMSO: >10 mg/mL; H₂O: insoluble
• originator: Kissei
• storage temp.: 2-8°C
• SMILES string: COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC
• InChI: 1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
• InChI key: NZHGWWWHIYHZNX-CSKARUKUSA-N
• Gene Information: human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)

Description

Application

The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.[1]

Biochem/physiol Actions

Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy.[2] It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE).[3]

Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing T_H1-mediated autoimmune diseases.

Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, inhibits mast cell degranulation, and inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro.

Features and Benefits

This compound was developed by Kissei. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• ppe: dust mask type N95 (US), Eyeshields, Gloves